API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://finance.yahoo.com/news/f2g-receives-complete-response-letter-113000837.html
https://www.pharmacompass.com/pdf/news/f2g-receives-crl-from-fda-for-nda-for-olorofim-for-the-treatment-14551.pdf
https://www.globenewswire.com/news-release/2022/10/13/2534044/0/en/F2G-to-Present-Interim-Results-from-Phase-2B-Open-Label-Study-of-Olorofim-in-Invasive-Fungal-Infections-at-IDWeek-2022.html
https://www.biospectrumasia.com/news/25/20293/novo-holdings-shionogi-offer-treatment-for-invasive-fungal-infections-in-europe-and-asia.html
https://www.prnewswire.com/news-releases/f2gs-olorofim-receives-both-fda-orphan-drug-designation-for-coccidioidomycosis-valley-fever-and-fda-qidp-designation-for-multiple-fungal-infections-301073101.html
https://www.prnewswire.com/news-releases/f2g-receives-us-fda-breakthrough-therapy-designation-for-olorofim-300954815.html
https://www.prnewswire.com/news-releases/f2g-receives-us-fda-breakthrough-therapy-designation-for-olorofim-300954815.html